Tag Archive | "NYSE:PFE"

Pfizer Names Veterinary Medical Director

Pfizer Names Veterinary Medical Director

Pfizer (NYSE:PFE) has announced the appointment of Dr. Christine Jenkins as Group Director.

Pfizer Names Veterinary Medical Director

According to an announcement made by the company, the Animal Health unit of Pfizer (NYSE:PFE) has named Dr. Christine Jenkins as the new Group Director of U.S. Veterinary Medical Services.

Clint Lewis, President of the U.S. Business for Pfizer (NYSE:PFE) Animal Health said, “We are excited to bring Jenkins on board to continue our commitment to address the unmet needs of the veterinarian community through collaboration with veterinary colleges and other industry groups.”

Pfizer Inc. (NYSE:PFE) shares were at 22.05 at the end of the last day’s trading. There’s been a 3.4% change in the stock price over the past 3 months.

Pfizer Names Veterinary Medical Director
Pfizer Inc. (NYSE:PFE) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 1.32
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.32
Zack’s Rank: 3 out of 14 in the industry

Posted in PharmaComments (0)

Pfizer Wins UK License

Pfizer Wins UK License

Pfizer (NYSE:PFE)’s heart pill Inspra has gained a new license in the UK.

Pfizer Wins UK License

Under this new license, the drug maker giant Pfizer (NYSE:PFE) can use its Inspra pill to be used for the treatment of cardiovascular mortality and morbidity in adult patients with chronic heart failure and left ventricular systolic dysfunction.

Pfizer (NYSE:PFE) said that this new license, which is available to the NHS this week, is a cost effective use of the money as it can cut hospital admissions, and has an incremental cost per QALY gained of £3,534.

Pfizer Inc. (NYSE:PFE) shares were at 22.34 at the end of the last day’s trading. There’s been a 2.8% change in the stock price over the past 3 months.

Pfizer Wins UK License
Pfizer Inc. (NYSE:PFE) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 1.32
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.32
Zack’s Rank: 3 out of 14 in the industry

Posted in Headlines, PharmaComments (0)

Pfizer Ending Commercialization Deal

Pfizer Ending Commercialization Deal

Pfizer (NYSE:PFE) and Biocon have announced the conclusion of their commercialization agreement.

Pfizer Ending Commercialization Deal

The drug maker giant Pfizer (NYSE:PFE) and Biocon have agreed to end their alliance to commercialize Biocon’s biosimilar versions of Insulin and Insulin analog products.

Diem Nguyen, General Manager- Biosimilars Pfizer (NYSE:PFE) said, “Pfizer (NYSE:PFE) continues to be dedicated to developing a broad portfolio of biosimilars medicines, including monoclonal antibodies and recombinant proteins products, both internally and through collaborations. In addition, we will continue to be active in our own research and business development efforts for diabetes, which represents a huge unmet medical need, and we remain committed to seeking new solutions to help physicians and patients.”

Pfizer Inc. (NYSE:PFE) stocks are currently standing at 22.65.

Pfizer Ending Commercialization Deal
Price History
Last Price: 22.65
52 Week Low / High: 16.63 / 22.8
50 Day Moving Average: 21.54
6 Month Price Change %: 28.1%
12 Month Price Change %: 11.5%

Posted in PharmaComments (0)

Pfizer To Push Vet Education In China

Pfizer To Push Vet Education In China

Pfizer (NYSE:PFE) and leading veterinary medical schools have collaborated for advanced veterinary medical education in China.

Pfizer To Push Vet Education In China

The animal health unit of Pfizer (NYSE:PFE) and International Veterinary Collaboration for China (IVCC), a consortium of leading veterinary medical schools in the United States and United Kingdom have signed a deal to collaborate with the Chinese Veterinary Medical Association (CVMA).

The deal is aimed at promoting advanced veterinary medical education and animal health in mainland China.

Dr. Michelle Haven, Vice President, Business Development, Global Alliances and Strategic Planning at Pfizer (NYSE:PFE) Animal Health said, “The memorandum of understanding marks a significant milestone for Pfizer (NYSE:PFE) Animal Health, our fellow IVCC partners and for China’s veterinary medicine profession.”

Pfizer Inc. (NYSE:PFE) shares were at 22.42 at the end of the last day’s trading. There’s been a 4.1% change in the stock price over the past 3 months.

Pfizer To Push Vet Education In China
Pfizer Inc. (NYSE:PFE) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 1.32
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.32
Zack’s Rank: 2 out of 14 in the industry

Posted in Headlines, PharmaComments (0)

Pfizer Expands Research Agreement

Pfizer Expands Research Agreement

Pfizer (NYSE:PFE) has expanded its three-year research agreement with the California Institute for Quantitative Biosciences.

Pfizer Expands Research Agreement

The drug maker giant Pfizer (NYSE:PFE) has reached an agreement to renew a three-year agreement with California Institute for Quantitative Biosciences (QB3) to collaborate on research projects at the University of California with the potential to transform world-class science into better medicine.

Uwe Schoenbeck, chief scientific officer of Pfizer (NYSE:PFE) External R&D Innovation said, “This collaboration has been very productive for Pfizer (NYSE:PFE), and a diversity of scientists from our numerous research centers have enjoyed the scientific interactions we have had with the QB3 network. This collaboration has been a model of success for us, and we look forward to an ever-closer relationship with this faculty in the coming years.”

Pfizer Inc. (NYSE:PFE) stocks are currently standing at 21.88.

Pfizer Expands Research Agreement
Price History
Last Price: 21.88
52 Week Low / High: 16.63 / 22.17
50 Day Moving Average: 21.49
6 Month Price Change %: 21.2%
12 Month Price Change %: 8.4%

Posted in PharmaComments (0)

Pfizer becomes Healthy Ageing Partner

Pfizer becomes Healthy Ageing Partner

Pfizer (NYSE:PFE) has become an official partner of the First World Congress on Healthy Ageing.

Pfizer becomes Healthy Ageing Partner

As a part of the move to reaffirm the company’s commitment to promote healthy and active ageing at all stages of life, the US based drug maker giant Pfizer (NYSE:PFE) has agreed to become an official partner of the First World Congress on Healthy Ageing.

Theresa Firestone, Regional President, Asia – Emerging Markets for Pfizer (NYSE:PFE) said, “Pfizer (NYSE:PFE) is proud to support this first-ever Congress as an important step in advancing the good work of the Malaysian Healthy Ageing Society.”

Pfizer Inc. (NYSE:PFE) stocks were at 21.91 at the end of the last day’s trading. There’s been a 4.3% change in the stock price over the past 3 months.

Pfizer becomes Healthy Ageing Partner
Pfizer Inc. (NYSE:PFE) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 1.32
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.32
Zack’s Rank: 3 out of 14 in the industry

Posted in PharmaComments (0)

Pfizer Cancels Insulin Deal

Pfizer Cancels Insulin Deal

Pfizer (NYSE:PFE) has decided to scrap its insulin development deal with Biocon.

Pfizer Cancels Insulin Deal

The US based drug maker giant Pfizer (NYSE:PFE) and Biocon have decided to end their partnership to commercialize Biocon’s biosimilar versions of insulin and insulin analog products.

Under this new deal, all rights licensed to Pfizer (NYSE:PFE) will revert to Biocon as of March 12.

“The companies have agreed that due to the individual priorities for their respective bio-similar businesses, it is in their best interest to move forward independently,” the two companies said in the joint statement.

Pfizer Inc. (NYSE:PFE) shares were at 21.54 at the end of the last day’s trading. There’s been a 5.6% change in the stock price over the past 3 months.

Pfizer Cancels Insulin Deal
Pfizer Inc. (NYSE:PFE) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 1.32
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.32
Zack’s Rank: 3 out of 14 in the industry

Posted in PharmaComments (0)

Pfizer Plans $3bn Floatation

Pfizer Plans $3bn Floatation

Pfizer (NYSE:PFE) has decided to raise $3 billion through a part-flotation of its animal health division.

Pfizer Plans $3bn Floatation

According to a Financial Times report, the US based drug maker giant Pfizer (NYSE:PFE) is weighing plans to raise about $3 billion this year through a part-flotation of its animal health division.

The company is in discussions with bankers over an initial public offering that would look to place up to 19.9 percent of the unit’s shares in the autumn.

Pfizer (NYSE:PFE) said that it is still evaluating all options for the division and is set to announce a decision in the coming months.

Pfizer Inc. (NYSE:PFE) stocks are currently standing at 21.19.

Pfizer Plans $3bn Floatation
Price History
Last Price: 21.19
52 Week Low / High: 16.63 / 22.17
50 Day Moving Average: 21.4
6 Month Price Change %: 19.9%
12 Month Price Change %: 9.4%

Posted in PharmaComments (0)

Sorry, the http://www.stocksandshares.tv/feed feed is not available at this time.
.
.